Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies

Clinical Immunology

Volumn 94, Issue 1, 2000, Pages 42-50

  Gordon, L K ^a,c   Eggena, M ^a,b   Targan, S R ^a,d   Braun, J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Inflammatory bowel disease; Mast cell; pANCA

Indexed keywords

AUTOANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANIMAL CELL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; COLON MUCOSA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAST CELL; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0033984312     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4805     Document Type: Article

References (57)

1. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class-II-restricted T lymphocytes. Annu. Rev. Immunol. 8:1990;773-794.
2. Brandtzaeg P., Bjerke K. Human peyer's patches: Lympho-epithelial relationships and characteristics of immunoglobulin-producing cells. Immunol. Invest. 18:1989;29-45.
3. Eisenbarth G. S., Jackson R. A., Pugliese A. Insulin autoimmunity: The rate limiting factor in pre-type I diabetes. J. Autoimmun. 5:1992;241-246.
4. Rankin G. B. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med. Clin. North Am. 74:1990;39-50.
5. Abreu-Martin M. T., Targan S. R. Regulation of immune responses of the intestinal mucosa. Crit. Rev. Immunol. 16:1996;277-309.
6. Sartor R. B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol. Clin. North Am. 24:1995;475-507.
7. Kagnoff M. F. A question of balance: Ups and downs of mucosal inflammation. J. Clin. Invest. 94:1994.
8. Duerr R. H., Targan S. R., Landers C. J., Sutherland L. R., Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology. 100:1991;1590-1596.
9. Yang H.-Y., Rotter J. I., Toyoda H., Landers C., Tyan D., McElree C. K., Targan S. R. Ulcerative colitis: A genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J. Clin. Invest. 92:1993;1080-1084.
10. Kallenberg C. G., Mulder A. H., Tervaert J. W. Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. Am. J. Med. 93:1992;675-682.
11. Hagen E. C., Ballieux B. E. P. B., Van Es L. A., Daha M. R., Van der Woude F. J. Antineutrophil cytoplasmic autoantibodies: A review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 81:1993;1996-2002.
12. Vecchi M., Bianchi M. B., Sinico R. A., Radice A., Meucci G., Torgano G., Omodei P., Forzenigo L., Landoni M., Arrigoni M., Pozzi C., de Franchis R. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: Sensitivity, specificity and recognition of putative antigens. Digestion. 5:1994;34-39.
13. Shanahan F., Duerr R. H., Rotter J. I., Yang H.-Y., Sutherland L. R., McElree C., Landers C. J., Targan S. R. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology. 103:1992;456-461.
14. Seibold F., Slametschka D., Gregor M., Weber P. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 107:1994;532-536.
15. Sandborn W. J., Landers C. J., Tremaine W. J., Targan S. R. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin. Proc. 71:1996;431-436.
16. Sandborn W. J., Landers C. J., Tremaine W. J., Targan S. R. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am. J. Gastroenterol. 90:1995;740-747.
17. Billing P., Tahir S., Calfin B., Gagne G., Cobb L., Targan S. R., Vidrich A. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am. J. Pathol. 147:1995;979-987.
18. Vidrich A., Lee J., James E., Cobb L., Targan S. R. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: Ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J. Clin. Immunol. 15:1995;293-299.
19. Walmsley R. S., Zhao M. H., Hamilton M. I., Brownlee A., Chapman P., Pounder R. E., Wakefield A. J., Lockwood C. M. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut. 40:1997;105-109.
20. Mulder A. H. L., Broekroelofs J., Horst G., Limburg P. C., Nelis G. F. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin. Exp. Immunol. 95:1994;490-497.
21. Stoffel M. P., Csernok E., Herzberg C., Johnson T., Carroll S. F., Gross W. L. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): A new seromarker for inflammatory bowel disease and associated disorders. Clin. Exp. Immunol. 104:1996;54-59.
22. Sobajima J., Ozaki S., Okazaki T., Osakada F., Sumita S., Mori K., Nakao K. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: Anti-cathepsin G and a novel antibody correlate with refractory type. Clin. Exp. Immunol. 105:1996;120-125.
23. Sobajima J., Ozaki S., Osakada F., Uesugi H., Shirakawa H., Yoshida M., Nakao K. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis: Non-histone chromosomal proteins, HMG1 and HMG2. Clin. Exp. Immunol. 107:1997;135-140.
24. Roozendaal C., Zhao M. H., Horst G., Lockwood C. M., Kleibeuker J. H., Limburg P. C., Nelis G. F., Kallenberg C. G. Catalase and alpha-enolase: Two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 112:1998;10-16.
25. Eggena M., Targan S. R., Iwanczyk L., Vidrich A., Gordon L. K., Braun J. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J. Immunol. 156:1996;4005-4011.
26. Barbas C. F., Kang A. S., Lerner R., Benkovic S. J. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA. 88:1991;7978-7982.
27. Cuevas E. C., Bateman A. C., Wilkins B. S., Johnson P. A., Williams J. H., Lee A. H., Jones D. B., Wright D. H. Microwave antigen retrieval in immunocytochemistry: A study of 80 antibodies. J. Clin. Pathol. 47:1994;448-452.
28. Taylor C. R., Shi S. R., Chaiwun B., Young L., Imam S. A., Cote R. J. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: Androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques [see comments]. Hum. Pathol. 25:1994;263-270.
29. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J. Leukocyte Biol. 61:1997;233-245.
30. Dvorak A. M. New aspects of mast cell biology. Int. Arch. Allergy Immunol. 114:1997;1-9.
31. Galli S. J., Hammel I. Mast cell and basophil development. Curr. Opin. Hematol. 1:1994;33-39.
32. Wu S.-K., Zeng K., Wilson I. A., Balch W. E. Structural insights into the function of the Rab GDI superfamily. Trends Biochem. Sci. 21:1996;472-477.
33. Donnelly S. R., Moss S. E. Annexins in the secretory pathway. Cell. Mol. Life Sci. 53:1997;533-538.
34. Gerst J. E. SNARES and SNARE regulators in membrane fusion and exocytosis. Cell. Mol. Life Sci. 55:1999;707-734.
35. Parseghian M., Harris D. A., Rishwain D. R., Hamkalo B. A. Characterization of a set of antibodies specific for three human histone H1 subtypes. Chromosoma. 103:1994;198-208.
36. Parseghian M. H., Henschen A. H., Kriegltein K. G., Hamkalo B. A. A proposal for a coherent mammalian histone H1 nomenclature correlated with amino acid sequences. Protein Sci. 3:1994;575-587.
37. Sommers S. C. Mast cells and paneth cells in ulcerative colitis. Gastroenterology. 51:1966;841-850.
38. Bischoff S. C., Wedemeyer J., Herrmann A., Meier P. N., Trautwein C., Cetin Y., Maschek H., Stolte M., Gebel M., Manns M. P. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology. 28:1996;1-13.
39. Bischoff S. C., Grabowsky J., Manns M. P. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig. Dis. Sci. 42:1997;394-403.
40. Balazs M., Illyes G., Vadasz G. Mast cells in ulcerative colitis. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 57:1989;353-360.
41. King T., Biddle W., Bhatia P., Moore J., Miner P. B. J. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig. Dis. Sci. 37:1992;490-495.
42. Fox C. C., Lichtenstein L. M., Roche J. K. Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig. Dis. Sci. 38:1993;1105-1112.
43. Raithel M., Matek M., Baenkler H. W., Jorde W., Hahn E. G. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int. Arch. Allergy Immunol. 108:1995;127-133.
44. Keranen U., Jarvinen H., Kiviluoto T., Kivilaakso E., Soinila S. Substance P- and vasoactive intestinal polypeptide-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Dig. Dis. Sci. 41:1996;1658-1664.
45. Yoon J. W., Yoon C. S., Lim H. W., Huang Q. Q., Kang Y., Pyun K. H., Hirasawa K., Sherwin R. S., Jun H. S. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science. 284:1999;1183-1187.
46. Kurts C., Carbone F. R., Krummel M. F., Koch K. M., Miller J. F. A. P., Heath W. R. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 398:1999;341-344.
47. Falcone M., Lee J., Patstone G., Yeung B., Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J. Immunol. 161:1998;1163-1168.
48. Tian J., Clare-Salzler M., Herschenfeld A., Middleton B., Newman D., Mueller R., Arita S., Evans C., Atkinson M. A., Mullen Y., Sarvetnick N., Tobin A. J., Lehmann P. V., Kaufman D. L. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 2:1996;1348-1353.
49. Atkinson M. A., Bowman M. A., Campbell L., Darrow B. L., Kaufman D. L., Maclaren N. K. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 94:1994;2125-2129.
50. Rotter J. I., Vadheim C. M., Rimoin D. L. Diabetes mellitus. King R. A., Rotter J. I., Motulsky A. G. The Genetic Basis of Common Diseases. 1992;413-481 Oxford Univ. Press, New York.
51. Toyoda H., Wang S.-J., Yang H.-Y., Redford A., Magalong D., Tyan D., McElree C., Pressman S., Shanahan F., Targan S. R., Rotter J. I. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology. 104:1993;741-748.
52. Yang H.-Y., Vora K. A., Targan S. R., Toyoda H., Beaudet A., Rotter J. I. Intercellular adhesion molecule 1 gene association with immunologic subsets of inflammatory bowel disease. Gastroenterology. 109:1995;440-446.
53. Hugot J.-P., Laurent-Puig P., Gower-Rousseau C., Olson J. M., Lee J. C., Beaugerie L., Naom I., Dupas J.-L., Van Gossum A., Orholm M., Bonaiti-Pellie C., Weissenbach J., Mathew C. G., Lennard-Jones J. E., Cortot A., Colombel J.-F., Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 379:1996;821-823.
54. Ohmen J. D., Yang H.-Y., Yamamoto K. K., Zhao H. Y., Ma Y., Bentley L. G., Huang Z., Gerwehr S., Pressman S., McElree C. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum. Mol. Genet. 5:1996;1679-1683.
55. Satsangi J., Parkes M., Louis E., Hashimoto L., Kato N., Welsh K., Terwilliger J. D., Lathrop G. M., Bell J. I., Jewell D. P. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat. Genet. 14:1996;199-202.
56. Duerr R. H., Barmada M. M., Zhang L., Davis S., Preston R. A., Chensny L. J., Brown J. L., Ehrlich G. D., Weeks D. E., Aston C. E. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am. J. Hum. Genet. 63:1998;95-100.
57. Eggena M. J. Autoimmun. 1999.